IMPORTANCE Brentuximab vedotin is a monomethyl auristatin E-conjugated monoclonal antibody directed against CD30. It represents a potential treatment for the CD30 + lymphoproliferative disorder lymphomatoid papulosis (LyP), which currently has no approved treatment.
L ymphomatoid papulosis (LyP) is a chronic papulonodular disorder characterized by recurrent, self-regressing crops of pruritic papules or nodules. [1] [2] [3] The lesions may ulcerate or become necrotic before they spontaneously regress and heal with scarring. 2, 3 The disorder represents a benign clonal proliferation of T lymphocytes and is part of a spectrum of cutaneous CD30 + lymphoproliferative disorders, which also includes primary cutaneous anaplastic large-cell lymphoma. 3 Although LyP confers an increased risk of lymphomas, such as Hodgkin lymphoma, anaplastic large-cell lymphoma, and mycosis fungoides, treatment does not alter this risk. 4 ,5 First-line treatments include topical corticosteroids, low-dose methotrexate, narrow-band UV-B light, and psoralen plus UV-A, 3 but no approved treatment is available to date.
Brentuximab vedotin, or SGN-35, is an antibody-drug conjugate directed against CD30. It consists of the chimeric monoclonal antibody brentuximab, which targets CD30, linked to monomethyl auristatin E, a chemotherapeutic agent that inhibits microtubule polymerization and causes G2/M cell cycle arrest. 6 Although brentuximab vedotin has received approval from the US Food and Drug Administration only for the treatment of relapsed classical Hodgkin lymphoma and refractory systemic anaplastic large-cell lymphoma, 7,8 limited evidence supports its use for LyP, primarily for patients with severe refractory disease. 6, 9 We present the outcomes of 12 patients with LyP who received brentuximab vedotin at our center from 2011 to 2017.
Methods

Study Design
We performed a subset analysis of patients enrolled in a 
Eligibility
All patients were 18 years of age or older with a clinical and histologic diagnosis of LyP. Patients were required to have scarring, more than 10 lesions, or active lesions on the face, hands,
Key Points
Question What is the overall response rate of brentuximab vedotin for lymphomatoid papulosis and does its clinical efficacy outweigh its adverse effects?
Findings In this case series, all 12 patients with lymphomatoid papulosis responded to brentuximab vedotin, including 7 patients (58%) who exhibited a complete response. Although the drug was well tolerated overall, 10 patients (83%) developed peripheral neuropathy.
Meaning Lymphomatoid papulosis is very responsive to brentuximab vedotin, but it should not be used for mild, asymptomatic disease and should be strictly reserved for truly severe and refractory disease; it could be amenable to lower dosing to minimize adverse events such as peripheral neuropathy. or feet to be eligible. Patients with borderline LyP/primary cutaneous anaplastic large-cell lymphoma, as well as those with a concomitant diagnosis of mycosis fungoides, were excluded from the analysis.
Efficacy Assessment and Response Criteria
The primary end point was the overall response rate. Patients with LyP who received at least 2 doses of brentuximab vedotin were evaluable for efficacy. Patients were assessed on day 1 of each cycle by counting the number of active LyP lesions.
Complete response was defined as no lesions, and PR was a 50% or greater reduction in lesion count from baseline. 10 A relapse was defined as loss of PR. Progressive disease was defined as an increase in lesion count of 25% or more. Stable disease was defined as a failure to attain a complete response or PR with no evidence of progressive disease.
Safety Assessment
Patients were monitored for adverse events (AEs) from the time of the initial infusion of the drug until 30 days after the final dose. Adverse events were reported and graded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
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Results
Patient Characteristics and Clinical Efficacy
The baseline demographic characteristics of the patients and their responses to therapy are shown in the Table. All patients had been pretreated, and all but 1 was refractory to multiple therapies. All patients were evaluable for efficacy. An example of the clinical response in patient 4 is depicted in Figure 1 . The duration of response for each patient is shown in Figure 2 .
The overall response rate was 100% and at 4 months was 80% (8 of 10 patients). Five patients relapsed, including patient 1 who was lost to follow-up for 18 months and presented with a relapse. She was subsequently retreated with 3 additional doses of brentuximab vedotin and has maintained a PR for more than 23 months. Only 1 patient, patient 12, has developed no new LyP lesions after discontinuation of treatment. Five patients continued to be followed up as of March 2017.
Safety
No patients died. The most frequent treatment-related AEs (≥10% and possibly related to the study drug) are shown in the Table. Grade 2 AEs were peripheral neuropathy (n = 5), fever (n = 2), fatigue (n = 1), hypertension (n = 1), abdominal pain (n = 1), constipation (n = 1), diarrhea (n = 1), and vomiting (n = 1). Adverse events of grade 3 or higher were neutropenia (n = 2) and dizziness or vertigo (n = 1). Three patients withdrew consent for treatment owing to AEs (2 with a rash due to hypersensitivity to the drug and 1 with a reaction to the infusion). For the 10 patients who developed neuropathy, the median time to onset was 4 weeks (range, 0.1-20 weeks), and the median duration was 35 weeks (range, 0.1-125 weeks). Grade 1 neuropathy occurred in 5 patients, and grade 2 neuropathy occurred in 5 patients, all of whom experienced improvement to grade 1. Dose reductions to 1.2 mg/kg for grade 2 neuropathy were made for 4 patients, 1 of whom later returned to the standard dose. Neuropathy resolved in 5 patients, with a median time to resolution of 0.9 weeks (range, 0.1-107 weeks).
Discussion
The results of our study suggest that LyP is very responsive to brentuximab vedotin, demonstrating an overall response rate of 100%. This response rate compares favorably with those of the traditional agents used for LyP, such as topical corticosteroids (46%), psoralen plus UV-A (56%), and methotrexate (57%-88%). 5, 12 The response rate is also higher than those for relapsed classical Hodgkin lymphoma (75%) 7 and refractory systemic anaplastic large-cell lymphoma (86%).
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Our results also show that brentuximab vedotin can control LyP with few infusions and potentially provide sustained responses. Only a single infusion was required to produce a response in all patients. Furthermore, 3 patients (patients 1, 4, and 12) continue to demonstrate longstanding responses. Patient 4 has maintained a PR for more than 60 months after she experienced a mild flare during treatment. Patient 12 continues to be in complete response for more than 26 months. Finally, patient 1 has been in PR for 23 months after being retreated for a relapse. Thus, for patients who do experience a relapse, brentuximab vedotin also offers the benefit of being able to be used again to treat an LyP flare.
The drug was well tolerated in patients with LyP. The most common AE was peripheral neuropathy in 10 patients (83%), which was reversible in 5 patients (50%). The high clinical activity and rapid onset of action of the drug suggest that lower or less frequent dosing may be equally effective yet less likely to induce neuropathy. One study found that a naked anti-CD30 antibody lacking the neurotoxic monomethyl auristatin E produced responses in LyP without causing neuropathy 13 ; however, this drug is no longer available.
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Limitations
This study is limited by a small sample size. Given the selfregressing and relapsing nature of LyP, evaluating responses to treatment is challenging, particularly in the 3 patients treated outside the trial who were not assessed at standardized follow-up intervals. Finally, although 4 patients received dose reductions to 1.2 mg/kg, they had received prior dosing of 1.8 mg/ kg, thus precluding comparisons of response rates between dosing regimens.
Conclusions
Lymphomatoid papulosis currently has no approved therapy. It can often be very difficult to treat, and some patients may exhaust standard treatments. For patients with extensive lesions or prominent pruritus, scarring, or ulceration, brentuximab vedotin may represent a valuable single-agent therapy. However, its use for patients with uncomplicated, mild, and asymptomatic LyP is not warranted, and it does not alter the risk of developing a second lymphoma. It may be best used to gain control over truly severe and refractory cases and to serve as a bridge to maintenance therapy with less aggressive therapies. It may also serve as an option for patients with liver disease or an extensive history of UV lightinduced skin cancer, precluding the use of methotrexate or psoralen plus UV-A, respectively. Although its safety profile is generally favorable, its efficacy must be balanced against the risk of AEs, particularly peripheral neuropathy. In rare cases, it may result in life-threatening AEs, such as progressive multifocal leukoencephalopathy 15 or neuropathy causing diaphragmatic paresis leading to respiratory failure. 16 Using brentuximab vedotin on an as-needed basis would reduce the risk of AEs while also likely extending its viability. Future investigations should focus on lower dosing or a less frequent dosing schedule. 
